XIV Eurasian Hematology-Oncology Congress - EHOC 2023

 

XIV Eurasian Hematology-Oncology Congress - EHOC 2023
R

Debates in MPNs: IFN-α is the Optimal 1L Treatment for Young PV Patients

By XIV Eurasian Hematology-Oncology Congress - EHOC 2023 FEATURING Rajko Kusec
By XIV Eurasian Hematology-Oncology Congress - EHOC 2023 FEATURING Rajko Kusec
9 views
February 21, 2024
Comments 0
Login to view comments. Click here to Login
MDS and MPN
12:28

Next Questions in MDS

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

G. Garcia-Manero

12 views
10:11

Case Presentation: A Patient With Polycythemia, Thrombocytopenia, & …

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

M. Mittelman

13 views
20:35

Treatment Options for MDS With Ring Sideroblasts: A Case-Based Discu…

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

M. Çetiner

9 views
14:36

Optimizing the Management of Low-Risk MDS

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

U. Platzbecker

19 views
19:32

Current State-of-the-Art in MDS

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

M. Mittelman

11 views
10:08

Advances and Unmet Needs in MPN Treatment

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

D. Cilloni

76 views
06:58

Debates in MPNs: IFN-α is the Optimal 1L Treatment for Young PV Pati…

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

R. Kusec

9 views
08:47

Debates in MPNs: Hydroxyurea is the Optimal 1L Treatment for Young P…

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

E. Eşkazan

17 views
07:58

Updates in the Prognosis and Treatment of Myelofibrosis

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

S. Koçak Toprak

30 views
10:50

CBL Mutated MPNs: Overview and Case Discussion

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A. Lucchesi

46 views
19:05

Key Biological and Clinical Developments in MPNs

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

T. Mughal

105 views